Treatment options in patients with prostate cancer (PCa) localized to the bones include the use of drugs making an attempt to improve their quality of life. In addition new therapies based on drugs with strong bone tropism have been developed. Samario 153 (Sm 153) is a radio-active compound that linked to a particular bifosfanate drug (EDTA) is able to reach and to bind to the bony-tessue carrying out its therapeutic effects. In this report we have analyzed the efficacy and the safety of a single treatment with Sm 153 in patients with metastatic bones spread of PCa causing a painful symptomatology.
PiffanelliA.. Terapia palliativa con radionuclidi delle metastasi ossee dolorose: risultati di uno studio osservazionale multicentrico (1996–1998).Notiziario di Medicina Nucleare1999; 11: 3–18.
2.
SerafiniA.N., HoustonS.J., RescheI.. Palliation of pain associated with metastatic bone cancer using samarium-153: a double-blind placebo-controlled clinical trial.J Clin Oncol1998; 16: 1574–81.
